Results 101 to 110 of about 5,279 (205)

Fact sheet for Paxlovid. Vietnamese

, 2021
Title from PDF caption (viewed on December 30, 2021)."OHA4029E12292021 VIETNAMESE"--Running footer.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core  

Hope and fear; Paxlovid for COVID-19 treatment: A Letter to the Editor [PDF]

Journal of Nephropharmacology, 2022
Alireza Pouramini, Maryam Khosravian, Fatemeh Kafi, Sina Bakhshaei, Hamid Reza Jahantigh, Payam Peymani, Neda Kianpour, Majid Foroutan   +7 more
doaj   +1 more source

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study

Journal of Infection and Public Health
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang, Weiting Zhang, Jing Zhou, Xinyue Ma, Changsong Wang, Mingyan Zhao, Kaijiang Yu   +6 more
doaj   +1 more source

The path to Paxlovid

C&EN Global Enterprise, 2022
openaire   +2 more sources

Reduced Viral Shedding Time in High-Risk COVID-19 Patients Infected by Omicron and Treated with Paxlovid: A Real-World Study from China

Infection and Drug Resistance
Wei Yang,1,* Yahui Peng,1,* Changsong Wang,1,* Hongliu Cai,2 Lina Zhang,3 Jun Xu,2 Yongjie Wang,4 Maonan Wang,4 Mingyan Zhao,1 Kaijiang Yu1 1Department of Critical Care Medicine, the First Affiliated Hospital of Harbin Medical University ...
Yang W, Peng Y, Wang C, Cai H, Zhang L, Xu J, Wang Y, Wang M, Zhao M, Yu K   +9 more
doaj  

Paxlovid: oral antiviral drug that acts on Main protease (Mpro) of SARS-CoV-2

openIl virus SARS-CoV-2, responsabile dell'insorgenza della patologia COVID-19, si è diffuso a livello globale generando una pandemia, che ha mobilitato numerosi ricercatori per poter giungere a ottenere terapie efficaci.
BRUNINO, ANGELICA
core  

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +1 more source

Real-world analysis of safety, tolerability, and adherence to nirmatrelvir-ritonavir (paxlovid) in primary care COVID-19 outpatients

Scientific Reports
This retrospective cross-sectional study aims to evaluate the safety, tolerability, and adherence of patients prescribed Nirmatrelvir-ritonavir (Paxlovid) in outpatient settings, focusing on its use in managing category 2 COVID-19 patients across three ...
Zahirah Zaharuddin, Nur Sabiha Md Hussin, Mahmathi Karuppannan   +2 more
doaj   +1 more source

Yi-Qing Oral Solution and Paxlovid combination for COVID-19: Efficacy and safety in a randomized controlled trial

Traditional Medicine and Modern Medicine
Background: The COVID-19 pandemic has exerted a significant social burden worldwide. Traditional Chinese medicine has emerged as a vital role in the clinical management of COVID-19.
Maimaititusun Yalikun, Xi Huang, Xueyi Zhu, Yuxue Cao, Jiming Zhang, Xin Ma, Jindong Hua, Jiaqi Liu, Xianjun Sun, Wenjing Du, Lingwen Kong, YanBo Ren, Hongli Xue, Baojun Liu, Yuanhao Zhang, Yang Lei, Zhen Gao, Weiyi Gong, Jingcheng Dong   +18 more
doaj   +1 more source

The problem of SARS-CoV-2 virus resistance to direct-acting antivirals

Биопрепараты: Профилактика, диагностика, лечение
INTRODUCTION. The high prevalence of mutations in the SARS-CoV-2 genome raises particular concerns about the resistance of the virus to current antiviral therapy, including inhibitors of the main protease, or 3C-like protease (3CLpro), and RNA-dependent ...
E. L. Gasich, E. N. Krotkova, A. D. Kasko, K. Yu. Bulda, A. G. Krasko, E. A. Dorofeeva, I. A. Karpov   +6 more
doaj   +1 more source